GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.27 USD | -2.70% |
|
-1.35% | -19.43% |
| Apr. 25 | News Highlights : Top Company News of the Day - Thursday at 5 PM ET | DJ |
| Apr. 25 | News Highlights : Top Company News of the Day - Thursday at 7 PM ET | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.27
USD
Average target price
84.95
USD
Spread / Average Target
+30.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.43% | 83.65B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences, Merck To Study Trodelvy, Keytruda Combination For Treatment of Lung Cancer
